Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
People with elevated, non-diabetic, levels of blood glucose are at risk of progressing to clinical type 2 diabetes and are commonly termed 'prediabetic'. The term prediabetes usually refers to high-normal fasting plasma glucose (impaired fasting glucose) and/or plasma glucose 2 h following a 75 g oral glucose tolerance test (impaired glucose tolerance). Current US guidelines consider high-normal HbA1c to also represent a prediabetic state. Individuals with prediabetic levels of dysglycaemia are already at elevated risk of damage to the microvasculature and macrovasculature, resembling the long-term complications of diabetes. Halting or reversing the progressive decline in insulin sensitivity and β-cell function holds the key to achieving prevention of type 2 diabetes in at-risk subjects. Lifestyle interventions aimed at inducing weight loss, pharmacologic treatments (metformin, thiazolidinediones, acarbose, basal insulin and drugs for weight loss) and bariatric surgery have all been shown to reduce the risk of progression to type 2 diabetes in prediabetic subjects. However, lifestyle interventions are difficult for patients to maintain and the weight loss achieved tends to be regained over time. Metformin enhances the action of insulin in liver and skeletal muscle, and its efficacy for delaying or preventing the onset of diabetes has been proven in large, well-designed, randomised trials, such as the Diabetes Prevention Program and other studies. Decades of clinical use have demonstrated that metformin is generally well-tolerated and safe. We have reviewed in detail the evidence base supporting the therapeutic use of metformin for diabetes prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Diabetes Prevention Study (Finland) [70] RCT IGT 522; 3.”
BackgroundStandards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 4×
“Improvements in glycaemia during treatment with metformin were insufficient to explain the improved cardiovascular outcomes observed in the UKPDS [52].”
BackgroundInfluentialCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 4×
“Participants in the DPP were followed up for long-term clinical outcomes in the DPP Outcomes Study (DPPOS), which is described separately below [69].”
BackgroundMethodInfluentialAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,163
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J. G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69701-8 · Cited by 1,799
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 2×
“STOP-NIDDM (International) [72, 73] RCT IGT 1429; 3.”
MethodImpaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“03) [106].”
Ratner, R. E., Christophi, C. A., Metzger, B. E., Dabelea, D., Bennett, P. H., Pi-Sunyer, X., Fowler, S., Kahn, S. E., & The Diabetes Prevention Program Research Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0772 · Cited by 867
TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., Bayley, N., Pollin, T. I., de Bakker, P. I. W., Shuldiner, A. R., Knowler, W. C., Nathan, D. M., & Altshuler, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062418 · Cited by 839
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects
Carlsson, L. M. S., Peltonen, M., Ahlin, S., Anveden, Å., Bouchard, C., Carlsson, B., Jacobson, P., Lönroth, H., Maglio, C., Näslund, I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112082 · Cited by 794
International Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Barr, E. L. M., Zimmet, P. Z., Welborn, T. A., Jolley, D., Magliano, D. J., Dunstan, D. W., Cameron, A. J., Dwyer, T., Taylor, H. R., Tonkin, A. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685628 · Cited by 719
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
de Jager, J., Kooy, A., Lehert, P., Wulffele, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010) · BMJ · doi:10.1136/bmj.c2181 · Cited by 702
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572 · cited 1×
“decreased with intensive lifestyle intervention [105].”
Lowering the Criterion for Impaired Fasting Glucose Is in Order
Genuth, S. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3331 · Cited by 559
Perreault, L., Pan, Q., Mather, K. J., Watson, K. E., Hamman, R. F., & Kahn, S. E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60525-x · Cited by 532
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes
Paulweber, B., Valensi, P., Lindström, J., Lalic, N., Greaves, C., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., et al. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1240928 · Cited by 469
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 1×
“Metformin relies on transport into cells via the organic cation transporter-1 (OCT1) for its clinical action, and polymorphisms of this transporter influence the efficacy of metformin in type 2 diabetes [49, 50].”
BackgroundKooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440 · cited 1×
“A second trial in insulintreated patients also demonstrated improved cardiovascular outcomes in patients randomised to metformin relative to placebo [53].”
BackgroundThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Freemark, M., & Bursey, D. (2001) · Pediatrics · doi:10.1542/peds.107.4.e55 · Cited by 433
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., Mielck, A., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1796 · Cited by 397
Natali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366
Diabetes Prevention Program Research Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02043.x · Cited by 363
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.36 · Cited by 358
Social Stigma in Diabetes: A Framework to Understand a Growing Problem for an Increasing Epidemic
Schabert, J., Browne, J. L., Mosely, K., & Speight, J. (2013) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-012-0001-0 · Cited by 339
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.5.1566 · Cited by 333 · cited 1×
“Modest, but significant, improvements in serum alanine aminotransferase (a marker of hepatic function) and C-reactive protein (a marker of systemic inflammation) were mediated by weight loss [110, 111].”
BackgroundClinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00006 · Cited by 318
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · cited 5×
“enhances the action of DPP4 inhibitors by either reducing the activity of DPP4 or enhancing secretion of GLP-1 [47, 48].”
BackgroundInfluentialWeight Loss of Black, White, and Hispanic Men and Women in the Diabetes Prevention Program
West, D. S., Prewitt, T. E., Bursac, Z., & Felix, H. C. (2008) · Obesity · doi:10.1038/oby.2008.224 · Cited by 295
Beneficial effects of metformin in normoglycemic morbidly obese adolescents
Kay, J. P., Alemzadeh, R., Langley, G., D'Angelo, L., Smith, P., & Holshouser, S. (2001) · Metabolism · doi:10.1053/meta.2001.28078 · Cited by 292
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
DEFRONZO, R. (1997) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00012-0 · Cited by 277
Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., et al. (2010) · Diabetes · doi:10.2337/db10-0543 · Cited by 271
Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2072 · Cited by 271
Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2518 · Cited by 262
Bray, G. A., Jablonski, K. A., Fujimoto, W. Y., Barrett-Connor, E., Haffner, S., Hanson, R. L., Hill, J. O., Hubbard, V., Kriska, A., Stamm, E., et al. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1212 · Cited by 259
The DREAM trial – Authors' reply
Gerstein, H. C., Yusuf, S., & Bosch, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69829-2 · Cited by 253
Rubin, R. R., Ma, Y., Marrero, D. G., Peyrot, M., Barrett-Connor, E. L., Kahn, S. E., Haffner, S. M., Price, D. W., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2008) · Diabetes Care · doi:10.2337/dc07-1827 · Cited by 242
Retinal Vascular Changes in Pre-Diabetes and Prehypertension
Nguyen, T. T., Wang, J. J., & Wong, T. Y. (2007) · Diabetes Care · doi:10.2337/dc07-0732 · Cited by 237
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Malin, S. K., Gerber, R., Chipkin, S. R., & Braun, B. (2012) · Diabetes Care · doi:10.2337/dc11-0925 · Cited by 229
Srinivasan, S., Ambler, G. R., Baur, L. A., Garnett, S. P., Tepsa, M., Yap, F., Ward, G. M., & Cowell, C. T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0241 · Cited by 227
Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage
Selvin, E., Lazo, M., Chen, Y., Shen, L., Rubin, J., McEvoy, J. W., Hoogeveen, R. C., Sharrett, A. R., Ballantyne, C. M., & Coresh, J. (2014) · Circulation · doi:10.1161/circulationaha.114.010815 · Cited by 223
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.4.977 · Cited by 218
The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group, Orchard, T. J., Temprosa, M., Barrett‐Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., et al. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03750.x · Cited by 214
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program
Perreault, L., Kahn, S. E., Christophi, C. A., Knowler, W. C., Hamman, R. F., & the Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc09-0523 · Cited by 209 · cited 1×
“Lower fasting glucose, weight loss, younger age and higher insulin secretion predicted reversion from IGT to normal glucose tolerance in the DPP [82].”
BackgroundPapatheodorou, K., Banach, M., Edmonds, M., Papanas, N., & Papazoglou, D. (2015) · Journal of Diabetes Research · doi:10.1155/2015/189525 · Cited by 203
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Knowler (2011) · doi:10.1001/archinternmed.2011.367 · Cited by 194
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
Knowler, W. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_16-1 · Cited by 194
Hivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, et al. (2011) · Diabetes · doi:10.2337/db10-1119 · Cited by 191
Pathophysiology of prediabetes
Ferrannini, E., Gastaldelli, A., & Iozzo, P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.005 · Cited by 177
Buysschaert, M., & Bergman, M. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.002 · Cited by 176
Dungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
Merlotti, C., Morabito, A., & Pontiroli, A. E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12270 · Cited by 167
Johnson, A. B., Webster, J. M., Sum, C. F., Heseltine, L., Argyraki, M., Cooper, B. G., & Taylor, R. (1993) · Metabolism · doi:10.1016/0026-0495(93)90284-u · Cited by 164
Marrero, D. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1005-9_1199 · Cited by 163
Cost-Effectiveness of the Interventions in the Primary Prevention of Diabetes Among Asian Indians
Ramachandran, A., Snehalatha, C., Yamuna, A., Mary, S., & Ping, Z. (2007) · Diabetes Care · doi:10.2337/dc07-0150 · Cited by 162
Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program
Mather, K. J., Funahashi, T., Matsuzawa, Y., Edelstein, S., Bray, G. A., Kahn, S. E., Crandall, J., Marcovina, S., Goldstein, B., Goldberg, R., et al. (2008) · Diabetes · doi:10.2337/db07-1419 · Cited by 161
Adherence to Preventive Medications
Walker, E. A., Molitch, M., Kramer, M. K., Kahn, S., Ma, Y., Edelstein, S., Smith, K., Johnson, M. K., Kitabchi, A., Crandall, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0454 · Cited by 161
Cheng, Y. J., Gregg, E. W., Geiss, L. S., Imperatore, G., Williams, D. E., Zhang, X., Albright, A. L., Cowie, C. C., Klein, R., & Saaddine, J. B. (2009) · Diabetes Care · doi:10.2337/dc09-0440 · Cited by 157
The role of metformin on vitamin B12 deficiency: a meta-analysis review
Niafar, M., Hai, F., Porhomayon, J., & Nader, N. D. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1157-5 · Cited by 154
Wright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153
Hopper, I., Billah, B., Skiba, M., & Krum, H. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711421687 · Cited by 149 · cited 2×
“While it seems reasonable to hypothesise that correction of prediabetic dysglycaemia might also reduce the future risk of adverse cardiovascular outcomes, further evidence from clinical trials is needed to demonstrate improved long-term outcomes in this setting [31].”
BackgroundImportance of the intestine as a site of metformin‐stimulated glucose utilization
Bailey, C. J., Mynett, K. J., & Page, T. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb13128.x · Cited by 147
Cryer, D. R., Nicholas, S. P., Henry, D. H., Mills, D. J., & Stadel, B. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.539 · Cited by 146
Baptista, T., Rangel, N., Fernández, V., Carrizo, E., Fakih, Y. E., Uzcátegui, E., Galeazzi, T., Gutiérrez, M. A. M., Servigna, M., Dávila, A., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.029 · Cited by 144
Perreault, L., Ma, Y., Dagogo-Jack, S. E., Horton, E. S., Marrero, D. G., Crandall, J. P., Barrett-Connor, E. L., & Program, F. T. D. P. (2008) · Diabetes Care · doi:10.2337/dc07-2390 · Cited by 144
Treating prediabetes with metformin: systematic review and meta-analysis.
Lily, M., Lilly, M., & Godwin, M. S. (2009) · PubMed · Cited by 142
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
Becker, M. L., Visser, L. E., van Schaik, R. H. N., Hofman, A., Uitterlinden, A. G., & Stricker, B. H. C. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328333bb11 · Cited by 139
HbA1c for the Diagnosis of Diabetes and Prediabetes: Is It Time for a Mid-Course Correction?
Cohen, R. M., Haggerty, S., & Herman, W. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2352 · Cited by 137
Twigg, S. M., Kamp, M. C., Davis, T. M., Neylon, E. K., & Flack, J. R. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00998.x · Cited by 136
Impact of A1C Screening Criterion on the Diagnosis of Pre-Diabetes Among U.S. Adults
Mann, D. M., Carson, A. P., Shimbo, D., Fonseca, V., Fox, C. S., & Muntner, P. (2010) · Diabetes Care · doi:10.2337/dc10-0752 · Cited by 131
Baptista, T., Martínez, J., Lacruz, A., Rangel, N., Beaulieu, S., Serrano, A., Arapé, Y., Martinez, M., de Mendoza, S., Teneud, L., et al. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100310 · Cited by 130
de Jager, J., Kooy, A., Schalkwijk, C., van der Kolk, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J., & Stehouwer, C. D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12128 · Cited by 129
Effect of metformin on glucose metabolism in the splanchnic bed
Bailey, C. J., Wilcock, C., & Day, C. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb09093.x · Cited by 129
Palmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128
Metformin for olanzapine‐induced weight gain: a systematic review and meta‐analysis
Praharaj, S. K., Jana, A. K., Goyal, N., & Sinha, V. K. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03783.x · Cited by 123
Green, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 121
Wu, R.-R., Jin, H., Gao, K., Twamley, E. W., Ou, J.-J., Shao, P., Wang, J., Guo, X.-F., Davis, J. M., Chan, P. K., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11091432 · Cited by 120
Metformin in Obese Children and Adolescents: The MOCA Trial
Kendall, D., Vail, A., Amin, R., Barrett, T., Dimitri, P., Ivison, F., Kibirige, M., Mathew, V., Matyka, K., McGovern, A., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2710 · Cited by 119
Body Size and Shape Changes and the Risk of Diabetes in the Diabetes Prevention Program
Fujimoto, W. Y., Jablonski, K. A., Bray, G. A., Kriska, A., Barrett-Connor, E., Haffner, S., Hanson, R., Hill, J. O., Hubbard, V., Stamm, E., et al. (2007) · Diabetes · doi:10.2337/db07-0009 · Cited by 117
Delahanty, L. M., Pan, Q., Jablonski, K. A., Watson, K. E., McCaffery, J. M., Shuldiner, A., Kahn, S. E., Knowler, W. C., Florez, J. C., Franks, P. W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1328 · Cited by 116 · cited 1×
“Of 16 SNPs known to be associated with obesity, only one was significantly associated with metformin for long-term weight loss (NEGR1 rs2815752); other SNPs were usually associated with shortor long-term weight loss with intensive lifestyle intervention, or irrespective of treatment [115].”
BackgroundScreening Adults for Pre-Diabetes and Diabetes May Be Cost-Saving
Chatterjee, R., Narayan, K. M. V., Lipscomb, J., & Phillips, L. S. (2010) · Diabetes Care · doi:10.2337/dc10-0054 · Cited by 111
Florez, H. J., Pan, Q., Ackermann, R. T., Marrero, D. G., Barrett-Connor, E. L., Delahanty, L. M., Kriska, A. M., Saudek, C. D., Goldberg, R. B., & Rubin, R. R. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2122-5 · Cited by 110
Lachin, J. M., Christophi, C. A., Edelstein, S. L., Ehrmann, D. A., Hamman, R. F., Kahn, S. E., Knowler, W. C., Nathan, D. M., & on behalf of the DPP Research Group (2007) · Diabetes · doi:10.2337/db06-0918 · Cited by 107 · cited 1×
“Weight loss accounted for 64 % of the beneficial effect of metformin versus placebo on diabetes risk [90].”
BackgroundRamachandran, A., Snehalatha, C., Mary, S., Selvam, S., Kumar, C. K. S., Seeli, A. C., & Shetty, A. S. (2009) · Diabetologia · doi:10.1007/s00125-009-1315-x · Cited by 105
Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients
Singh, A., Kumar, A., Karmakar, D., & Jha, R. (2013) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.123143 · Cited by 105
Carrizo, E., Fernández, V., Connell, L., Sandia, I., Prieto, D., Mogollón, J., Valbuena, D., Fernández, I., de Baptista, E. A., & Baptista, T. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.007 · Cited by 102
Olshansky, E., Sacco, D., Fitzgerald, K., Zickmund, S., Hess, R., Bryce, C., McTigue, K., & Fischer, G. (2008) · The Diabetes Educator · doi:10.1177/0145721708327304 · Cited by 100
Cardiac troponin: a critical review of the case for point-of-care testing in the ED
Bingisser, R. M., Cairns, C. B., Christ, M., Hausfater, P., Lindahl, B., Mair, J. M., Panteghini, M., Price, C. P., & Venge, P. (2012) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2012.03.004 · Cited by 99
Effect of metformin on patients with impaired glucose tolerance
Li, C. L., Pan, C. Y., Lu, J. M., Zhu, Y., Wang, J. H., Deng, X. X., Xia, F. C., Wang, H. Z., & Wang, H. Y. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00090.x · Cited by 97
Goldberg, R. B., Temprosa, M., Haffner, S., Orchard, T. J., Ratner, R. E., Fowler, S. E., Mather, K., Marcovina, S., Saudek, C., Matulik, M. J., et al. (2009) · Diabetes Care · doi:10.2337/dc08-0494 · Cited by 94
Bertram, M., Lim, S. S., Barendregt, J. J., & Vos, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1661-8 · Cited by 92
Guidelines for the Prevention Management and Care of Diabetes Mellitus
Khatib, O. (2006) · Cited by 86
Fu, J.-F., Liang, L., Zou, C.-C., Hong, F., Wang, C.-L., Wang, X.-M., & Zhao, Z.-Y. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803453 · Cited by 84
Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study
Wang, M., Tong, J.-H., Zhu, G., Liang, G.-M., Yan, H., & Wang, X. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.021 · Cited by 82
Florez, J. C., Jablonski, K. A., Taylor, A., Mather, K. J., Horton, E. S., White, N. H., Barrett-Connor, E. L., Knowler, W. C., Shuldiner, A. R., & Pollin, T. I. (2012) · Diabetes Care · doi:10.2337/dc11-2301 · Cited by 78
Treating prediabetes with metformin: systematic review and meta-analysis
Lily, L. (2016) · Cited by 75
Wu, T., Thazhath, S. S., Bound, M. J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.004 · Cited by 74
Björkhem-Bergman, L., Asplund, A. B., & Lindh, J. D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109353461 · Cited by 72
Arman, S., Sadramely, M. R., Nadi, M., & Koleini, N. (2008) · Saudi Medical Journal · doi:10.15537/1658-3175.4426 · Cited by 72
Rubin, R. R., Ma, Y., Peyrot, M., Marrero, D. G., Price, D. W., Barrett-Connor, E., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2010) · Diabetes Care · doi:10.2337/dc10-1033 · Cited by 71
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., McAteer, J. B., Sandhu, M. S., Wareham, N. J., Barroso, I., Franks, P. W., Altshuler, D., & Knowler, W. C. (2007) · Diabetologia · doi:10.1007/s00125-007-0891-x · Cited by 70
Many Americans Have Pre-Diabetes and Should Be Considered for Metformin Therapy
Rhee, M. K., Herrick, K., Ziemer, D. C., Vaccarino, V., Weintraub, W. S., Narayan, K. M. V., Kolm, P., Twombly, J. G., & Phillips, L. S. (2010) · Diabetes Care · doi:10.2337/dc09-0341 · Cited by 68
Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada
Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., & O'Brien, J. A. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01330.x · Cited by 67
The Diabetes Prevention Program Research Group (2006) · Obesity · doi:10.1038/oby.2006.246 · Cited by 67
Metabolic effects of metformin in patients with impaired glucose tolerance
Lehtovirta, M., Forsén, B., Gullström, M., Häggblom, M., Eriksson, J. G., Taskinen, M. ‐., & Groop, L. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00539.x · Cited by 66
Alcohol consumption and diabetes risk in the Diabetes Prevention Program
Crandall, J. P., Polsky, S., Howard, A. A., Perreault, L., Bray, G. A., Barrett-Connor, E. L., Brown-Friday, J., Whittington, T., Foo, S. T., Ma, Y., et al. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27382 · Cited by 65
Snehalatha, C., Mary, S., Selvam, S., Sathish Kumar, C. K., Shetty, S. B. A., Nanditha, A., & Ramachandran, A. (2009) · Diabetes Care · doi:10.2337/dc09-0676 · Cited by 64
5. Prevention or Delay of Type 2 Diabetes
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s008 · Cited by 61
Depression Symptoms and Antidepressant Medicine Use in Diabetes Prevention Program Participants
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.830 · Cited by 60
Krakoff, J. A., Clark, J. M., Crandall, J. P., Wilson, C., Molitch, M. E., Brancati, F. L., Edelstein, S. L., & Knowler, W. C. (2010) · Obesity · doi:10.1038/oby.2010.21 · Cited by 60
Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
Chatterjee, R., Narayan, K. M. V., Lipscomb, J., Jackson, S. L., Long, Q., Zhu, M., & Phillips, L. S. (2013) · Diabetes Care · doi:10.2337/dc12-1752 · Cited by 57
Ehret, M. J., Goethe, J. W., Lanosa, M., & Coleman, C. I. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05274yel · Cited by 55
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine
Chen, C.-H., Chiu, C.-C., Huang, M., Wu, T., Liu, H.-C., & Lu, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.013 · Cited by 54
Prediabetes in Patients Treated With Antipsychotic Drugs
Manu, P., Correll, C. U., Winkel, R. V., Wampers, M., & Hert, M. D. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06822 · Cited by 54
Effect of Intervention in Subjects with High Risk of Diabetes Mellitus in Pakistan
Iqbal Hydrie, M. Z., Basit, A., Shera, A. S., & Hussain, A. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/867604 · Cited by 54
Gómez-Díaz, R. A., Talavera, J. O., Canché-Pool, E. B., Ortiz-Navarrete, V. F., Solórzano‐Santos, F., Mondragón-González, R., Valladares‐Salgado, A., Cruz, M., Aguilar-Salinas, C. A., & Wacher, N. H. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.003 · Cited by 54
Fontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.005 · Cited by 53
Palmer, A. J., & Tucker, D. M. D. (2012) · Primary Care Diabetes · doi:10.1016/j.pcd.2011.10.006 · Cited by 53
Apovian, C. M. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79231-x · Cited by 52
Metformin - The gold standard:a scientific handbook
Bailey, C. J., Campbell, I. W., Chan, J. C. N., Davidson, J. A., Howlett, H. C. S., & Ritz, P. (2007) · Cited by 51
Cuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.001 · Cited by 51
Florez, J. C., Jablonski, K. A., McAteer, J. B., Franks, P. W., Mason, C. C., Mather, K. J., Horton, E. S., Goldberg, R. B., Dabelea, D., Kahn, S. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044424 · Cited by 51
Liu, Y., & Hong, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12128 · Cited by 50
Management of Type 2 Diabetes Mellitus: Strategies for improving diabetes care
Institute for Clinical Systems Integration, & Bergenstal, R. M. (1999) · Postgraduate Medicine · doi:10.3810/pgm.1999.01.503 · Cited by 50
Treatment of clinical insulin resistance in children: a systematic review
Quinn, S. M., Baur, L. A., Garnett, S. P., & Cowell, C. T. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00697.x · Cited by 48
Diabetes Prevention Program (DPP) Research Group, Hamman, R. F., Horton, E., Barrett-Connor, E., Bray, G. A., Christophi, C. A., Crandall, J., Florez, J. C., Fowler, S., Goldberg, R., et al. (2015) · Diabetes · doi:10.2337/db14-0333 · Cited by 46 · cited 1×
“diabetes incidence in the other groups [85].”
Cost Effectiveness of Preventive Screening Programmes for Type 2 Diabetes Mellitus in Germany
Schaufler, T., & Wolff, M. (2010) · Applied Health Economics and Health Policy · doi:10.2165/11532880-000000000-00000 · Cited by 46
Garnett, S. P., Baur, L. A., Noakes, M., Steinbeck, K. S., Woodhead, H., Burrell, S., Chisholm, K. W., Broderick, C. R., Parker, R., De, S., et al. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-575 · Cited by 46
Icks, A., Rathmann, W., Haastert, B., Gandjour, A., Holle, R., John, J., Giani, G., & on behalf of the KORA Study Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02108.x · Cited by 46
Scarpello, J. H. (2001) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514010010010501 · Cited by 44
Wen-ying, Y. (2001) · Zhonghua neifenmi daixie zazhi · Cited by 44
Thondam, S. K., Cross, A., Cuthbertson, D. J., Wilding, J. P., & Daousi, C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03675.x · Cited by 43
Reducing the Risk of Developing Diabetes
Ransom, T. P. P., Goldenberg, R., Mikalachki, A., Prebtani, A. P. H., & Punthakee, Z. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.013 · Cited by 43
Friedman, A. N., Marrero, D. G., Ma, Y., Ackermann, R. T., Narayan, K. M. V., Barrett-Connor, E. L., Watson, K. E., Knowler, W. C., & Horton, E. S. (2008) · Diabetes Care · doi:10.2337/dc08-0148 · Cited by 41
Feher, M. D., Al‐Mrayat, M., Brake, J., & Leong, K. S. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070050501 · Cited by 39
Snehalatha, C., Simon, M., Joshi, V. V., & Ramachandran, A. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.005 · Cited by 38
Background and recruitment data for the U.S. Diabetes Prevention Program.
Fujimoto, W. Y. (2000) · PubMed · Cited by 38
Pollin, T. I., Isakova, T., Jablonski, K. A., de Bakker, P. I. W., Taylor, A., McAteer, J. B., Pan, Q., Horton, E. S., Delahanty, L. M., Altshuler, D., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002895 · Cited by 38
Efficacy of Primary Prevention Interventions When Fasting and Postglucose Dysglycemia Coexist
Ramachandran, A., Arun, N., Shetty, A. S., & Snehalatha, C. (2010) · Diabetes Care · doi:10.2337/dc09-1150 · Cited by 38
the DPPOS Research Group, Marrero, D., Pan, Q., Barrett-Connor, E., de Groot, M., Zhang, P., Percy, C., Florez, H., Ackermann, R., Montez, M., et al. (2014) · Quality of Life Research · doi:10.1007/s11136-013-0436-3 · Cited by 37
Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report
Tyrberg, M., Melander, A., Lövestam‐Adrian, M., & Lindblad, U. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00759.x · Cited by 37
Armato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35
Yuen, H. L. A., Sugeng, Y., Weiland, T. J., & Jelinek, G. A. (2010) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2010.00503.x · Cited by 34
Baptista, T., Sandia, I., Lacruz, A., Rangel, N., Mendoza, S. D., Beaulieu, S., Contreras, Q., Galeazzi, T., & Vargas, D. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32801182e6 · Cited by 32
Andreadis, E., Katsanou, P., Georgiopoulos, D., Tsourous, G., Yfanti, G., Gouveri, E., & Diamantopoulos, E. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0028-1087177 · Cited by 31
Retnakaran, R. R., Qi, Y., Harris, S. B., Hanley, A. J., & Zinman, B. (2011) · Diabetes Care · doi:10.2337/dc11-0046 · Cited by 30
Changes in Albumin Excretion in the Diabetes Prevention Program
Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc08-1400 · Cited by 26
Passey, M. E., Shrestha, R. N., Bertram, M., SCHOFIELD, D. J., Vos, T., Callander, E. J., Percival, R., & Kelly, S. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-16 · Cited by 26
Glucose perturbations and cardiovascular risk: Challenges and opportunities
Rydén, L., & Mellbin, L. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112451581 · Cited by 25
Ramachandran, A., Snehalatha, C., Satyavani, K., Sivasankari, S., & Viswanathan, V. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.08.009 · Cited by 25
Ramachandran, A., Snehalatha, C., Shetty, A. S., & Nanditha, A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03392.x · Cited by 22
Hoffmann, V. P., Case, M. G., & Jacobson, J. G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05580 · Cited by 19
Carrizo, E., Fernández, V., Sandia, I., Prieto, D., Mogollón, J., Connel, L., Valbuena, D., Fernández, I., de Baptista, E. A., & Baptista, T. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.006 · Cited by 13
The University of Oxford Diabetes Trials Unit.
Holman, R. R., & Nicholls, M. (2015) · PubMed · Cited by 11
REVISTA VENEZOLANA DE ENDOCRINOLOGIA Y METABOLISMO
Ablan, F. (2008) · Cited by 10
Successful strategy to improve glucose tolerance in Thai obese youth.
Numbenjapon, N., Nakavachara, P., Santiprabhob, J., Kiattisakthavee, P., Wongarn, R., & Likitmaskul, S. (2010) · PubMed · Cited by 5
Incretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
Cited by
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
“At this time, the presence of prediabetes necessitates intensive lifestyle intervention, although targeted medical pharmacological therapy with metformin, for example, may be optimal for certain individuals.(251)”
BackgroundMetformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Estrogen–gut microbiome axis: Physiological and clinical implications
Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.025 · Cited by 993
Prediabetes and Cardiovascular Disease
Brannick, B., & Dagogo-Jack, S. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.001 · Cited by 293
Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 275
Metadata
- Authors
- Hostalek, U., Gwilt, M., & Hildemann, S.
- Venue
- Drugs
- Published
- 2015-06-10
- Volume
- 75
- Issue
- 10
- Pages
- 1071-1094
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W564948178
- Cited by
- 278
- References
- 200
- FWCI
- 15.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.